Recent discussions on X about Recursion Pharmaceuticals (RXRX) have been ignited by the company’s acquisition of Exscientia and expanded partnerships with major pharmaceutical giants like Sanofi and Roche. Many users are intrigued by the potential of Recursion’s AI-driven drug discovery platform, with some expressing excitement over how these moves could position the company as a leader in biotech innovation. The buzz reflects a renewed focus on the stock’s long-term prospects amidst a volatile market.
However, not all chatter is uniformly positive, as some participants on X have raised concerns over recent stock price declines and insider sales, questioning the near-term stability of RXRX. Despite these worries, others point to the company’s platform enhancements and pipeline growth in rare diseases and oncology as reasons for optimism. The conversation remains dynamic, with sharp divides on the stock’s trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Recursion Pharmaceuticals Insider Trading Activity
Recursion Pharmaceuticals insiders have traded $RXRX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- CHRISTOPHER GIBSON (Chief Executive Officer) has made 0 purchases and 7 sales selling 1,018,175 shares for an estimated $5,298,964.
- NAJAT KHAN (Chief R&D Commercial Officer) sold 36,599 shares for an estimated $202,172
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Recursion Pharmaceuticals Hedge Fund Activity
We have seen 165 institutional investors add shares of Recursion Pharmaceuticals stock to their portfolio, and 148 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 4,864,474 shares (+20.7%) to their portfolio in Q2 2025, for an estimated $24,614,238
- VANGUARD GROUP INC added 3,783,201 shares (+11.7%) to their portfolio in Q2 2025, for an estimated $19,142,997
- STATE STREET CORP removed 1,905,719 shares (-14.6%) from their portfolio in Q2 2025, for an estimated $9,642,938
- ARK INVESTMENT MANAGEMENT LLC removed 1,826,871 shares (-5.2%) from their portfolio in Q2 2025, for an estimated $9,243,967
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,793,008 shares (-28.0%) from their portfolio in Q2 2025, for an estimated $9,072,620
- DIMENSIONAL FUND ADVISORS LP removed 1,682,722 shares (-98.0%) from their portfolio in Q2 2025, for an estimated $8,514,573
- LAURION CAPITAL MANAGEMENT LP removed 1,547,407 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $7,829,879
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Recursion Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $RXRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 09/11/2025
To track analyst ratings and price targets for Recursion Pharmaceuticals, check out Quiver Quantitative's $RXRX forecast page.
Recursion Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $RXRX recently. We have seen 2 analysts offer price targets for $RXRX in the last 6 months, with a median target of $6.5.
Here are some recent targets:
- Gil Blum from Needham set a target price of $8.0 on 09/11/2025
- Vikram Purohit from Morgan Stanley set a target price of $5.0 on 07/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
